Positive results reaffirm plans to advance ATL1102 to P2b
Filed with ASX · · 6 pages · English
Percheron Therapeutics Limited on 6ix
Earlier from Percheron Therapeutics
- Suspension from Official Quotation
- AGM Presentation 2019
- Dosing completed in ATL1102 Phase II DMD trial
- Appendix 4C - quarterly
- Response to ASX Price Query
Later from Percheron Therapeutics
- Antisense Therapeutics Limited - Listed Options raise $5.5M
- Quarterly Update & Appendix 4C
- Results in DMD unlock value creation potential of ATL1102
- Appointment of US-based Consultant Medical Director
- Trial Met Primary & Exceeded Secondary Endpoint Expectations
Follow Percheron Therapeutics into a list and get an email when it puts out news.
Follow Percheron Therapeutics